Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, Fatih Süheyl Ezgü et al.|New England Journal of Medicine|2016Cited by 555
Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1Pramod K. Mistry, Michel Peterschmitt, Elena Lukina et al.|JAMA|2015Cited by 156
Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with <scp>G</scp>aucher disease type 1: The phase 3 ENGAGE trialPramod K. Mistry, Michel Peterschmitt, Elena Lukina et al.|American Journal of Hematology|2017Cited by 99
De novo variants in KDM2A cause a syndromic neurodevelopmental disorderEric N. Anderson, Ivan Ivanovski, Stephan Drukewitz et al.|Universität Zürich, ZORA|2026Cited by 0